Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Shares Up 5.9 Percent on New Dx Patent Award

NEW YORK, July 11 (GenomeWeb News) - Shares in Stratagene were up 5.9 percent, or $.51, at $9.14 in late-afternoon trading after the company said it won a US patent for its FullVelocity technology.

 

The patent, No. 6,893,819, is entitled "Methods for Detection of a Nucleic Acid by Sequential Amplification." According to Stratagene, it covers "novel methods for the detection of infectious agents, cancer and genetic traits."

 

It is the fifth patent the company has won for the FullVelocity technology.

 

The technology described in the patent "can enhance FullVelocity and Taq-based chemistries by offering increased multiplexing capabilities at a potentially lower cost," Stratagene president and CEO Joseph Sorge said in a statement.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.